drugset / Trial / NCT05503693
A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered AP303 will be assessed in healthy adult subjects.
Timeline
- Start
- 2022-12-06
- Primary completion
- 2023-07-21
- Completion
- 2023-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP303 | Unknown | 50 ug | Oral |
| Subject | AP303 | Unknown | 150 ug | Oral |
| Subject | AP303 | Unknown | 300 ug | Oral |
| Subject | AP303 | Unknown | 600 ug | Oral |
Indications
No indication recorded.